Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
ZacksVKTX’s shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
VKTX’s shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.